Protein-Based Age Clocks Predict Cancer, Heart Disease and Death Over 28 Years
A massive European study shows proteomic age clocks rival lifestyle risk factors in predicting mortality and chronic disease.
Summary
Researchers measured biological aging in over 17,000 Europeans using blood protein profiles and tracked health outcomes for up to 28 years. They found that people whose proteins indicated accelerated aging faced significantly higher risks of dying and developing cardiovascular disease, dementia, and several cancers. Strikingly, organ-specific protein clocks — measuring aging in individual organs like the lung or kidney — predicted cancers in those same organs more accurately than a general aging score. Smoking, heavy drinking, and physical inactivity were the lifestyle factors most strongly linked to accelerated protein-based aging. The predictive power of these proteomic clocks matched that of traditional risk factors like smoking history, positioning them as powerful new biomarkers for early disease risk assessment.
Detailed Summary
Biological age — how old your body is at a molecular level — can diverge dramatically from your birth year. Proteomic clocks, which estimate biological age from patterns in hundreds of blood proteins, offer a new window into this gap and may transform how clinicians identify people at high risk of chronic disease before symptoms appear.
This large-scale study examined 17,473 participants from the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort, using SomaScan plasma proteomics to derive both a global proteomic age score and organ-specific clocks. Researchers tracked 24 incident chronic diseases and all-cause mortality over up to 28 years, with replication in the independent Whitehall II study.
The global age gap — a composite score combining multiple proteomic clocks — was significantly associated with smoking, alcohol consumption, and physical inactivity. Crucially, accelerated proteomic aging predicted higher risk of all-cause mortality, cardiovascular diseases, dementia, and cancers of the liver, upper aero-digestive tract, lung, and kidney. Lung, kidney, and stomach cancers showed even stronger associations with their corresponding organ-specific aging clocks, suggesting these targeted measures capture disease-relevant biology that a global score misses.
Perhaps most compelling for clinicians: the proteomic clocks performed comparably to classical lifestyle risk factors in predicting mortality. This positions them not merely as research curiosities but as potentially actionable clinical tools — especially for identifying high-risk individuals who appear healthy by conventional measures.
Important caveats apply. Proteomics at this scale is expensive and not yet routine in clinical settings. The study is observational, so causality cannot be established. Additionally, this summary is based on the abstract alone, meaning methodological details, effect sizes, and nuanced findings from the full paper are not available for evaluation.
Key Findings
- Accelerated proteomic aging strongly predicted all-cause mortality, rivaling traditional lifestyle risk factors in predictive power.
- Organ-specific protein clocks predicted lung, kidney, and stomach cancers more accurately than a global aging score.
- Smoking, alcohol consumption, and physical inactivity were the lifestyle factors most associated with faster proteomic aging.
- Proteomic clocks linked biological aging to cardiovascular disease, dementia, and multiple cancers over 28 years of follow-up.
- Findings replicated in the independent Whitehall II cohort, strengthening confidence in the biomarker's validity.
Methodology
The study analyzed SomaScan plasma proteomic data from 17,473 EPIC cohort participants, deriving global and organ-specific proteomic age clocks and following participants for up to 28 years for 24 chronic disease endpoints and mortality. Findings were independently replicated in the Whitehall II study. The design is prospective observational, limiting causal inference.
Study Limitations
The study is observational, precluding causal conclusions about whether proteomic aging drives disease or merely reflects shared underlying processes. SomaScan proteomics remains expensive and is not yet routinely available in clinical practice. This summary is based on the abstract only; full methodological details, effect sizes, and subgroup analyses could not be assessed.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: